Previous in vivo and in vitro studies on NSCLC reported inhibition of PI3 kinase and Akt phosphorylation in response to MOR antagonists, with subsequent attenuation of cell proliferation invasion and migration [7,14,18,20]. Here, AKT1 is linked to non-small cell lung carcinoma.